IMPORTANCE Among children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia, the rate of 5-year disease-free survival is 10% to 20%. Approval of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option. However, tisagenlecleucel is expensive, with a current list price of $475 000 per one-time administration.
B
-cell acute lymphoblastic leukemia (B-ALL) is the most common malignant neoplasm diagnosed in children, accounting for 20% to 30% of the overall incidence of childhood cancer. 1, 2 Owing to its presentation as a systemic disease, treatment for B-ALL has been based primarily on chemotherapy. 3 However, among patients with relapsed or refractory B-ALL, rates of 5-year disease-free survival are only 10% to 20%. [4] [5] [6] The recent approval of chimeric antigen receptor T-cell (CAR-T) therapies represents a new and potentially curative treatment option for B-ALL. 7 Tisagenlecleucel, the first CAR-T therapy approved, is indicated for use in pediatric patients with relapsed or refractory B-ALL. 7 Evidence for tisagenlecleucel demonstrated higher rates of response, eventfree survival, and overall survival than other therapies used in pediatric patients with B-ALL who were heavily pretreated. 8 However, follow-up for patients receiving tisagenlecleucel is limited, with a maximum duration of less than 4 years; therefore, uncertainty remains around its long-term benefit. Tisagenlecleucel is expensive, currently listed at $475 000 per a one-time administration. 9 Although the manufacturer has discussed an outcomes-based payment agreement, in which only patients who respond to treatment will be required to pay, 10 the list price and payment agreement do not include additional costs, such as hospital markup or health care use for preparation, administration, management, or adverse events. The objective of this analysis was to estimate the long-term survival and value of tisagenlecleucel for pediatric patients with B-ALL.
Methods

Study Design
Because this study model uses already available evidence from studies, the Colorado Multiple Institutional Review Board waived approval for this study and for patient consents. A decision analytic model extrapolated trial evidence from 3 studies 11 (B2202, enrolled patients from April 8, 2015 , to November 23, 2016; B2205J, enrolled patients from August 14, 2014 , to February 1, 2016; and B2101J, enrolled patients from March 15, 2012 , to November 30, 2015 and aggregated all costs and outcomes expected from tisagenlecleucel. The analysis was from a payer perspective and estimated outcomes over a patient lifetime horizon. Data were analyzed from December 1, 2017, to March 31, 2018. The decision analytic model included a short-term decision tree and a long-term semi-Markov partitioned survival model ( Figure 1 ). The decision tree tracked a patient from initiation of treatment through assessment of response. Initiation of treatment was to undergo leukapheresis in preparation for tisagenlecleucel infusion. At the first decision tree event node, patients had the following 3 options: continue with the tisagenlecleucel infusion after undergoing leukapheresis, discontinue before infusion because of adverse events (AEs) or manufacturing failure, or die before receiving the infusion. Those who discontinued the CAR-T arm owing to AEs were assumed to not be able to tolerate other active therapies and therefore transitioned to receive no further antileukemic therapy (ie, palliative care only). Those who discontinued the CAR-T arm owing to manufacturing failure were assumed to receive clofarabine.
The second event node of the decision tree assessed a patient's response to treatment, which had the 3 following options: alive and responding to treatment, alive and not responding to treatment, or dead before assessment of response. The model allowed for patients to receive or not receive stem cell transplantation (third event node of the decision tree) after assessment of response. After the decision tree, patients moved to the semi-Markov partitioned survival model, where they transitioned between the following 3 health states: alive and responding to treatment, alive and not responding to treatment, and dead. Patient movement through each of the health states was estimated from the direct extrapolation of event-free survival and overall survival curves. The published Kaplan-Meier curves were digitized from November 1, 2017, to November 30, 2017, using the algorithm by Guyot and colleagues 12 to impute patient-level time-to-event data. The fitted model curves included the distributional forms of Weibull, exponential, log-normal, log-logistic, and Gompertz. The base-case distributional form was analyzed between December 1, 2017, and December 31, 2017, and was selected separately for each curve based on best model fit using Akaike information criterion values, visual comparison with KaplanMeier curves, and plausibility of long-term extrapolation. The eAppendix in the Supplement provides more details regarding the study design. Flattening in the tail of the survival curves was observed for both tisagenlecleucel and clofarabine. Standard parametric models likely underestimate survival when flattening in the tail exists; therefore, we used a flexible parametric model to account for this flattening. 13 We first fit a parametric curve function to the portion of the curve that was downward sloping. After the fitted curve intersected the flat portion (ie, slope of 0) of the Kaplan-Meier curve, a knot was introduced. After the knot, mortality occurred only owing to all-cause mortality. This flexible parametric approach extrapolated the published survival curves to 5 years, after which patients who were alive and responding to treatment were considered to be long-term survivors and effectively cured. 14 Accordingly, patients who were alive and not responding to treatment died within 5 years of treatment completion. Mortality after 5 years was based on the age-and sex-adjusted all-cause risks of mortality. 14 Modifications for excess disease-related mortality for long-term survivors was modeled by applying a standardized mortality ratio
Key Points
Question What is the long-term survival and value of tisagenlecleucel for pediatric patients with relapsed or refractory leukemia?
Findings In this decision-analytic modeling study using deidentified data, cost-effectiveness analysis generated an incremental cost-effectiveness ratio between $37 000 and $78 000 per quality-adjusted life-year gained over a patient lifetime horizon, with more than 40% of those initiating tisagenlecleucel treatment becoming long-term survivors.
Meaning Tisagenlecleucel seems to be priced in alignment with its clinical benefits, although its value depends on assumptions around long-term survival.
of 9.1 to the mortality risk. 15 Model outcomes included patient survival, quality-adjusted survival, and health care costs.
A full description of model assumptions, along with their rationale, can be found in eTable 1 in the Supplement.
Intervention and Comparator
The modeled cohort included patients younger than 25 years with B-ALL that was refractory or in second or later relapse. The intervention of interest was tisagenlecleucel. Evidence for tisagenlecleucel was abstracted from single-arm trials, which resulted in challenges selecting the most appropriate comparator therapy. Because a matching-adjusted indirect comparison was not possible owing to the lack of patient-level data and the available aggregated evidence being from single-arm trials, 16 we chose the comparator with evidence from the most similar patient population. We engaged stakeholders and clinical experts in relapsed or refractory leukemia to inform our decision and considered various comparisons, including clofarabine monotherapy, clofarabine combination therapy, and blinatumomab. Clofarabine monotherapy was chosen as the comparator because the trial populations for both tisagenlecleucel and clofarabine monotherapy were most similar in relation to demographics and disease severity. eTable 2 in the Supplement describes the population characteristics for those receiving tisagenlecleucel and clofarabine. eTable 3intheSupplement details the treatment regimen for the intervention and comparator. Furthermore, both clofarabine and tisagenlecleucel are indicated by the US Food and Drug Administration for relapsed or refractory acute lymphoblastic leukemia after at least 2 prior regimens. Blinatumomab was not selected as the comparator owing to the heterogeneity in the patient populations (eg, age, bone marrow blast level, and prior lines of therapy) in the evidence for tisagenlecleucel and blinatumomab.
Model Inputs
Clinical inputs included survival, AEs, and quality of life. The clinical inputs that informed the model are detailed in Table 1 . 8, 14, [17] [18] [19] [20] [21] [22] [23] [24] Further detail on clinical model inputs can be found in eTables 4-11 in the Supplement. Economic inputs included the treatment acquisition cost, potential hospital markup, and health care use. Payment for tisagenlecleucel was assumed only for responders at 1 month, based on expected agreements between the manufacturer and payers. Both the tisagenlecleucel and clofarabine treatment arms assumed inpatient administration and were thus subject to potential hospital markup. Because the contracts between hospitals and payers related to hospital markup are still being developed for tisagenlecleucel and are confidential, we engaged stakeholders and CAR-T experts to inform the hospital markup for tisagenlecleucel. The assumed markup was capped at $100 000 based on comments from stakeholders and CAR-T experts that some facilities may not negotiate a markup while other facilities may charge a markup. Costs associated with health care use resulting from administration and monitoring were included in the model. The cost of a hospitalization for treatment administration was estimated using a fee-for-service approach, which included a per diem cost for hospital days and added costs of therapies administered during the hospitalization. Additional costs were included for AEs that were expected to prolong hospitalization (cytokine release syndrome) or extend beyond discharge (ie, B-cell aplasia). Future related and unrelated medical costs were included for long-term survivors. All costs were adjusted to 2017 US dollars. A full description of the economic inputs that informed the model can be found in eTables 12-14 in the Supplement.
Sensitivity Analyses
A probabilistic sensitivity analysis was conducted to assess variation in all model inputs simultaneously. Five thousand iterations were run and the percentage of all iterations that fell beneath common value thresholds of $50 000, $100 000, and $150 000 per quality-adjusted life-year (QALY) gained were computed.
Scenario Analyses
Previous literature has noted unique characteristics of decision analytic modeling for potentially curative therapies in the pediatric population, such as the discount rate, duration of benefit observed in trials, point of treatment initiation, and inclusion of future health care costs. 25 For each of these characteristics, we conducted a scenario analysis. The resulting values from these scenario analyses served to bound the range of cost-effectiveness.
Discount Rate
In the United Kingdom, the National Institute for Health and Care Excellence recommends a discount rate of 1.5%, compared with the typical 3.5% discount rate, when an intervention is expected to result in substantial improvement in health over a long period of time. 26 In the United
States, there has been no recommendation on differential discounting for therapies with long-term and significant health improvement. In our base-case analysis, we used a discount rate of 3%, based on recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine. 27 However, in this scenario analysis, we used a discount rate of 1.5% for both costs and outcomes.
Duration of Trial Benefit
When tisagenlecleucel was approved by the US Food and Drug Administration, the median follow-up of Study B2101J, the trial with the longest duration, was only 18.6 months. 11 Therefore, our decision analytic model required extrapolation of trial re- sults. We tested the assumptions made through extrapolation in 2 scenario analyses. First, we estimated the number of years the benefit observed in the trial would need to continue to produce an incremental cost-effectiveness ratio beneath commonly cited value thresholds. Second, instead of using a flexible parametric model that accounted for the flattening observed in the Kaplan-Meier curves, we used standard parametric modeling to serve as a lower bound of survival and a conservative estimate of the long-term value.
Treatment Initiation
With tisagenlecleucel, patients initiate treatment by undergoing leukapheresis. However, patients who undergo leukapheresis may never receive the infusion owing to AEs, manufacturing failures, or death. In our base-case analysis, we started our model at leukapheresis; this approach is similar to an intent-to-treat analysis for a randomized clinical trial. In this scenario analysis, we started the model at infusion instead.
Future Health Care Costs
Criticism of models that include future unrelated health care costs is common, despite recommendations by the Second Panel on Cost-Effectiveness in Health and Medicine to include both future related and unrelated health care costs. 27 Our base-case analysis included future related and unrelated health care costs for long-term survivors; however, in this scenario analysis, these future health care costs were excluded.
Results
Base Case
The total discounted costs over the patient lifetime horizon as well as the total undiscounted and discounted life-years (LYs) and QALYs are detailed in Table 2 . Tisagenlecleucel had a total discounted cost of approximately $667 000, with discounted LYs gained of 10.34 years and 9.28 QALYs gained. A total of 42.6% of patients who underwent leukapheresis were considered to be long-term survivors. Clofarabine had a total discounted cost of approximately $337 000, with discounted life-years gained of 2.43 years and 2.10 QALYs gained. A total of 10.8% of patients receiving clofarabine treatment were considered to be long-term survivors. The incremental cost-effectiveness ratio between tisagenlecleucel and clofarabine was approximately $46 000 per QALY gained.
Sensitivity Analysis
The mean incremental cost-effectiveness ratio from the probabilistic sensitivity analysis was $43 416 per QALY gained. All iterations were below a threshold of $100 000 per QALY gained; however, these sensitivity analyses did not account for uncertainty around survival curve parameters. Table 3 presents the results of each scenario analysis as compared with the base-case estimates. The cost-effectiveness estimates ranged from $37 000 to $77 500 per QALY gained across the scenario analyses.
Scenario Analyses
Discount Rate
From the base-case analysis, the costs did not change, but the LYs and QALYs increased owing to the smaller discount rate. This change increased the incremental difference in health outcomes and resulted in a more favorable cost-effectiveness ratio of $37 000 per QALY gained (Table 3) .
Duration of Trial Benefit
The trial-specific benefit would need to continue for at least 7 years after infusion to produce an incremental costeffectiveness ratio less than $150 000 per QALY gained, for 12 years to be less than $100 000 per QALY gained, and for 36 years to be less than $50 000 per QALY gained. Figure 2 shows the cost-effectiveness estimate over all time horizons, from 1 year to lifetime. Furthermore, using standard parametric modeling, the LY for tisagenlecleucel decreased to 5.15 years and the QALYs for tisagenlecleucel decreased to 4.49 years. For clofarabine, the LYs decreased to 0.66 years and the QALYs decreased to 0.49 years. This change increased the incremental cost-effectiveness ratio to $77 500 per QALY gained (Table 3) .
Treatment Initiation
When the model started at treatment infusion, the incremental cost-effectiveness ratio slightly increased. Starting at leukapheresis, the incremental costs were $329 498 and incremental QALYs were 7.2 years. This change resulted in an incremental cost-effectiveness ratio of $45 871. When the model started at infusion, the incremental costs increased to $454 892 and incremental QALYs increased to 9.1 years. This change slightly increased the incremental cost-effectiveness ratio to $50 000 per QALY gained (Table 3) .
Future Health Care Costs
In the final scenario analysis, we removed future related and unrelated medical costs. This resulted in a more favorable costeffectiveness estimate of $40 700 per QALY gained (Table 3 ).
Discussion
Our base-case findings suggest that tisagenlecleucel in pediatric patients with B-ALL provides clinical benefits in quality-adjusted and overall survival compared with clofarabine. This result translates into cost-effectiveness estimates that meet commonly cited value thresholds under current model assumptions. The results were robust through sensitivity analyses, with no resulting incremental costeffectiveness ratio extending beyond $100 000 per QALY gained. Owing to the unique characteristics of modeling potentially curative therapies in the pediatric population, multiple scenario analyses were conducted to test model assumptions. From these scenario analyses, the lowest costeffectiveness estimate of approximately $37 000 resulted when the discount rate was reduced to 1.5%. The highest cost-effectiveness estimate of approximately $78 000 resulted when standard parametric modeling was used to estimate long-term survival from these therapies. We acknowledge that considerable uncertainty remains around the long-term benefit of tisagenlecleucel owing to limited available evidence; however, with current evidence and assumptions, tisagenlecleucel meets commonly cited value thresholds over a patient lifetime horizon, assuming payment for treatment acquisition for responders at 1 month.
With evidence for tisagenlecleucel coming from singlearm trials, comparator selection was challenging. We chose the comparator with the most similar baseline population characteristics, but also acknowledge that blinatumomab is frequently used to treat this patient population. We suspect that tisagenlecleucel would remain cost-effective compared with blinatumomab. A study conducted by other researchers found the incremental cost-effectiveness ratio of tisagenlecleucel vs blinatumomab was similar to the incremental cost-effectiveness ratio of tisagenlecleucel vs clofarabine (ie, $3000 more per QALY).
28 Selection of the comparator is important in cost-effectiveness estimates; however, tisagenlecleucel for pediatric B-ALL likely remains below commonly cited value thresholds despite the chosen comparator.
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Limitations
This analysis is limited primarily by the lack of comparative evidence between the intervention and comparator; this lack complicates the calculation of the incremental difference in outcomes (denominator of the incremental costeffectiveness ratio) between tisagenlecleucel and clofarabine. First, cross-trial differences in the population between tisagenlecleucel and clofarabine, and not necessarily the different treatments, may contribute to the differences in health outcomes observed between trials. This lack of comparative evidence also prohibits the ability to account for uncertainty about survival curve parameters in sensitivity analyses; therefore, the sensitivity analyses likely underestimate the uncertainty in this evidence. Second, follow-up on event-free survival and overall survival is limited for tisagenlecleucel, which required assumptions regarding longterm results and defining when a patient is effectively cured.
A 5-year cure point was used based on evidence from clinical 15 and economic 14 literature. The cure point was established to determine at what point after trial follow-up patients who were alive but not responding to treatment would die. A later cure point (after 5 years) would result in slightly more favorable cost-effectiveness estimates. Similarly, an earlier cure point (shorter than 5 years) would result in slightly less favorable cost-effectiveness estimates. Uncertainty in long-term survival was partially accounted for in scenario analyses that evaluated different modeling assumptions and time horizons. Although scenario analysis results represent a reasonable lower bound on effectiveness based on current data, it is always possible that a worst-case scenario might present itself (eg, development of neutralizing antibodies with high rates of subsequent relapse). Value should therefore be reassessed once data with longer follow-up are available. Third, mechanisms for payment of tisagenlecleucel are still largely unknown (eg, bundled payment vs fee-for-service, amount of hospital markup, and outcomes-based pricing), necessitating assumptions around costs and payment of these therapies. Clinical experts and other key stakeholders were engaged to inform our assumptions, but value should also be reassessed once more information on payment for this novel therapy is available. Finally, because there is some expectation that tisagenlecleucel might be curative, we considered using a mixture cure model. However, without access to patient-level data, we elected to use a flexible parametric model with an assumed cure-point to approximate the aggregated data with fewer assumptions.
Conclusions
After extrapolating trial results over a patient lifetime horizon, we estimated that more than 40% of pediatric patients who undergo leukapheresis in preparation for tisagenlecleucel therapy will be considered long-term survivors, compared with approximately 10% of pediatric patients considered long-term survivors after receiving comparator therapy. With the evidence available at this time, tisagenlecleucel seems to be priced in alignment with benefits observed over a patient lifetime horizon. The findings are sensitive to the longterm benefit forecasting, but based on currently available evidence and extrapolation assumptions, the cost-effectiveness likely is between $37 000 and $78 000 over a patient lifetime horizon. As payers are negotiating their coverage and reimbursement of tisagenlecleucel, they should consider the uncertainties in the evidence and the assumptions made in this analysis. Novel payment models consistent with the present evidence may reduce the risk and uncertainty in long-term value and be more closely aligned with ensuring high-value care.
30,31 Financing cures in the United States is challenging owing to the high up-front price, rapid uptake, and uncertainty in long-term outcomes 31,32 ; however, innovative payment models are an opportunity to address some of these challenges and to promote patient access to novel and promising therapies. Based on mean time from CAR-T therapy to stem cell transplantation estimated by Lee et al. 11 Patients received a single full course of CAR-T therapy.
CAR-T therapies are considered an end-of-line treatment with no clinical evidence on re-treatment. After year five, survivors experienced a mortality risk profile consistent with that of a long-term survivor, after adjustments were made for excess mortality.
At year five, those who were alive were assumed to be effectively cured. A standardized mortality ratio of 9.1 was applied to all-cause risk of death for longterm survivors. 12 Any person alive but not responding to treatment transitioned to death by the end of year five.
Those alive at year five are considered long-term survivors.
All patients who transitioned to the alive and not responding to treatment health state received palliative chemotherapy.
The intervention and comparator therapies are considered end-of-line treatments.
Patients who discontinued CAR-T due to an AE before receiving the infusion received no further antileukemic/antilymphomic therapy.
Those who experienced a severe AE would be unable to tolerate further active therapy.
Patients who did not receive CAR-T therapy due to a manufacturing failure received the active comparator.
Those who experienced a manufacturer failure would be able to tolerate further active therapy.
The model included costs and outcomes associated with grade 3/4 AEs.
Less severe adverse events are not expected to significantly impact patient health or costs. The cost of a hospital admission for treatment administration included the per diem cost for hospital days and the costs of therapies administered during the hospitalization.
Future bundled payments were assumed to approximate the cost of the resources used under a fee-for-service framework.
Population Characteristics
Evidence was abstracted from single-arm trials, which resulted in challenges selecting the most appropriate comparator therapies. Because a matching-adjusted indirect comparison (MAIC) was not possible due to the lack of patient-level data and the available aggregated evidence being from single-arm trials, we chose the comparator with evidence from the most similar patient populations. Based on clinical expert input and available evidence, we chose clofarabine monotherapy as the comparator because the trial populations for both tisagenlecleucel and clofarabine monotherapy were most similar in relation to demographics and disease severity. eTable 2 presents the population characteristics for the intervention and selected comparator. 
Model Structure
The decision analytic model structure included a short-term decision tree and a long-term semi-Markov partitionedsurvival model. The decision tree calculated the costs and consequences from treatment initiation to assessment of response, which was approximately one month. 4 From the decision tree, patients moved to the semi-Markov partitioned-survival model, where they were then tracked for a lifetime time horizon. The purpose of the decision tree was to stratify the cohort by which treatment they received. Further, the decision tree allowed for allocation of upfront costs by treatment and the stratification of the cohort by response status, which becomes important when considering outcomes-based pricing.
For the decision tree, the CAR-T arm included patients who were eligible for tisagenlecleucel and underwent leukapheresis. At the first decision tree event node of the CAR-T arm, patients had three possibilities: 1) continue with the tisagenlecleucel infusion after undergoing leukapheresis; 2) discontinue before infusion but after leukapheresis because of adverse events or manufacturing failure; or 3) die before receiving the infusion but after leukapheresis. Patients with infusion pending were excluded from our analysis because outcomes data were not available for them. Those who discontinued the CAR-T treatment arm due to adverse events were assumed to not be able to tolerate other active therapies and therefore transitioned to receive no further antileukemic therapy (i.e., palliative care only). Those who discontinued the CAR-T arm due to manufacturing failure were assumed to receive clofarabine. Responses were assessed for patients who received the tisagenlecleucel infusion (second event node of decision tree), which could be: alive and responding to treatment; alive and not responding to treatment; or dead before assessment of response. The model was flexible enough to allow for patients to receive or not receive stem cell transplantation (third event node of decision tree) based on percentages reported in available evidence. The decision tree's comparator arm followed a similar pathway to the CAR-T arm, tracking the patient from comparator treatment initiation through assessment of response and receipt of stem cell transplantation.
From the decision tree, the cohort was assigned to three mutually exclusive health states in a semi-Markov partitioned survival model that followed patients for the remainder of their lifetime using survival curve evidence. The three health states included: 1) alive and responding to treatment, 2) alive and not responding to treatment, and 3) death from B-ALL or other causes. Patients transitioned between states during predetermined cycles (one month) over a lifetime time horizon. The "alive and responding to treatment" health state included all patients who were alive and responding to treatment (complete or partial responders). The "alive and not responding to treatment" health state included all patients who were alive that did not respond to treatment or relapsed after previously responding to treatment. Patients in the "alive and not responding to treatment" health state remained in this health state until they died from their B-ALL malignancy or other causes. Patients not responding to treatment received palliative chemotherapy. End-of-life hospice care costs were assigned to each death event. Health state occupancy was derived using partitioned survival techniques involving the direct extrapolation of EFS and OS Kaplan-Meier curves:
alive and responding to treatment (t)=P(EFS, t) alive and not responding to treatment (t)=(P(OS, t)-P(EFS, t)) death (t) = 1-P(OS, t)
Although the decision tree separated the cohort based on response status, survival curves were not available stratified by response status for all treatments. Further, definitions of response may vary between treatments; thus, survival curves were based on aggregated cohort data and not stratified by response status. Therefore, in our model, there is no structural link between response status and survival. Response status, from the decision tree, is only important when assigning payment within the tisagenlecleucel outcomes based-pricing scenarios.
Similar to modeling done by Hettle and colleagues, 5 we assessed treatment response and survival over the first five years following treatment completion by extrapolating data from published Kaplan-Meier curves. After year five, survivors experienced a mortality risk profile consistent with that of a long-term survivor, with adjustments made for excess mortality.
In summary, the two-part decision analytic model included four stages:
• Collectively, we describe Stages 2-4 as a semi-Markov partitioned survival model that models the cohort from assessment of response until death.
The model was developed in Microsoft Excel.
Curve Digitization
Kaplan-Meier curves from the evidence were digitized using the algorithm by Guyot and colleagues 6 to impute patient-level time-to-event data. We extracted data points from the digitized copies of published survival curves, 7 then used the extracted values, the number of surviving patients at each time interval, and maximum likelihood functions to estimate the underlying individual patient data. Values were extrapolated for five years following treatment completion. The model curves considered included the distributional forms of Weibull, exponential, lognormal, log-logistic, and Gompertz. The base-case distributional form was selected separately for each curve based on best model fit using Akaike information criterion (AIC) values and visual comparison. A series of flexible cubic spline models were also considered, but they were not good fits for the Kaplan-Meier curves used in the model, based on AIC and visual comparison. Monthly transition probabilities were derived using the survival function with the best model fit. These steps allowed for the extrapolation of survival beyond the observed trial evidence to a time-period of approximately five years, while also keeping as close as possible to the observed trial survival signals. For the comparator, there were no published EFS curves. Therefore, the EFS curve was derived from available OS data by assuming a proportional relationship between EFS and OS observed in the tisagenlecleucel trial. 4, 5 Due to the potentially curative nature of tisagenlecleucel, apparent flattening of survival curves was observed. To account for this flattening, we explored the best time points to split survival curves into separate analyses. For example, a parametric curve function could be fit from 0 to 12 months, and then a separate parametric curve function could be fit from one to five years with a flatter slope than the first function to account for the plateau expected toward the end of the curves. The time point chosen to split the analyses was empirically driven based on curve fit, and was selected once the fitted curve intersected the flattening (i.e., slope of 0) observed in the Kaplan Meier curve.
Model Parameters
The base-case analysis took a third-party payer perspective and focused on direct medical care costs only. Outcomes were estimated over a lifetime time horizon using a monthly cycle to capture the potential lifetime impacts of short-term and ongoing morbidity and mortality. Costs and outcomes were discounted at 3% per year. For tisagenlecleucel, the payment strategy used in the base-case analysis was payment only for responders at one month, consistent with public statements the manufacturer has made. 
Model Inputs
Model inputs were estimated from information provided by manufacturers as well as from published literature. The inputs that informed the model are described below.
Response to Treatment Treatment response rates were obtained from published literature and information provided from manufacturers. The initial response rates used in the short-term decision tree are provided in eTable 4. It is important to note that EFS and OS curves were not stratified by response status. Response status is used in our model when assigning payment within the tisagenlecleucel outcomes-based pricing scenarios. The denominator is the number of people who received an infusion for tisagenlecleucel and the number of people who initiated the chemotherapy regimen for clofarabine. Within treatment, the percentages sum to 100, with response and death categories being mutually exclusive and exhaustive.
Transition Probabilities and Survival Base-case survival was derived from parametric fits to the intervention's available EFS and OS Kaplan-Meier curves. Individual transition probabilities were calculated as described in the Model Structure section. eTable 5 details the evidence used to calculate transition probabilities. No published event-free survival curve; therefore, the event-free survival curve was derived from available overall survival data for clofarabine, by assuming the same proportional relationship seen in the tisagenlecleucel curve.
Overall Survival
Pooled overall survival curve for Study B2202, B2205J, and B2101J 4 14.8% (9/61) 3 
Adverse Events
The model included any grade 3/4 AE that occurred in ≥ 5% of patients in any of the treatments and comparators, as listed in eTable 9. Any grade of hypogammaglobulinemia was modeled based on clinical expert guidance that treatment with IVIG might still be necessary for grades 1 and 2. Costs and disutilities associated with AEs are described later. 
Utilities
To adjust for quality of life, utilities were applied for each model health state. Health state utilities were derived from publicly available literature and applied to the disease states. Utilities were derived from self-reported quality of life data in pediatric patients undergoing SCT (for the alive and not responding to treatment health state) and in pediatric patients that were long-term survivors of relapsed pediatric ALL (for the alive and responding to treatment health state). 14 Patient data were collected and mapped to the EuroQol-5D (for the alive and not responding to treatment health state) and Health Utilities Index 2 (for the alive and responding to treatment health state).
Utilities remained consistent within the cohort across different treatments. The utilities for each model health state are presented in eTable 10. The utility for a long-term survivor was assumed to equal the utility of the alive and responding to treatment health state. 5 It is worth noting, however, that the long-term survivor utility (equivalent to the alive and responding to treatment utility) is similar to the general population mean EQ-5D score for the age band corresponding to each population, which is 0.922 for ages 18- Disutilities were applied for each treatment, including pre-treatment regimens for tisagenlecleucel, to account for the potential reduction in quality of life while receiving treatment. eTable 11 details the disutilities and duration of reduction in quality of life applied for each treatment. All treatment-related disutilities were included in Stage 1 of the model.
Further, disutilities for AEs were considered. All disutilities due to AEs associated with tisagenlecleucel, stem cell transplantation, and chemotherapy were assumed to be accounted for in the treatment disutility estimates provided in eTable 11. Only occurrences of grade 3/4 CRS were expected to impact quality of life outside of what was included in the treatment disutilities. In alignment with a mock health technology appraisal conducted for regenerative medicines, a utility of 0 was applied for any grade 3 or higher case of CRS. 5 This disutility lasted for eight days, which equated to the median duration of ICU stay due to CRS. 
Economic Inputs
Economic inputs included costs associated with treatment acquisition, hospital mark-up, healthcare utilization, and adverse events.
Treatment Acquisition Costs
The unit cost for each treatment is reported in eTable 12. The regimens used for each treatment can be found in eTable 2. The average sales price (ASP) for all treatments was used, except for tisagenlecleucel, where wholesale acquisition cost (WAC) was the only available estimate. Patients that discontinued the CAR-T pathway before receiving the tisagenlecleucel infusion were not charged the tisagenlecleucel acquisition cost. The manufacturer of tisagenlecleucel covers the cost of leukapheresis. The cost of a hospital admission for treatment administration (tisagenlecleucel and clofarabine) was estimated using a fee-for-service approach, which included the per-diem cost for hospital days and added on costs of therapies administered during the hospitalization. Hospitalizations might in the future be paid through a bundled payment mechanism (e.g., for Medicare beneficiaries); however, the bundled payment for the tisagenlecleucel hospital admission is unknown at this time. Hospitalization costs associated with the administration of tisagenlecleucel were included regardless of treatment response status or outcomes-based payment strategy.
The cost of SCT was retrieved from the literature. The total cost for pediatric allogeneic SCT, inflated to present value dollars, was approximately $560,000.
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Based on recommended practices by the Second Panel of Cost-Effectiveness, future related and unrelated healthcare costs were included in the model for patients who were alive and responding to treatment after five years. The average monthly healthcare costs by age band were assigned to patients for the remainder of their lifetime if they were alive and responding to treatment after five years.
Adverse Event Costs
The cost of the hospitalization for treatment administration was assumed to include the cost of adverse events (AEs) except for AEs that were expected to prolong the hospitalization (CRS) or extend beyond discharge (B cell aplasia).
The unit cost for a grade 3/4 episode of CRS included the cost of tocilizumab (calculated by multiplying the unit
